Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Pembrolizumab-induced acute thrombosis

(2018) Kei Kunimasa et al.   MEDICINE

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Risk of Arterial Thromboembolism in Patients With Cancer

(2017) Babak B. Navi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABO Blood Group and Risk of Thromboembolic and Arterial DiseaseCLINICAL PERSPECTIVE

(2016) Senthil K. Vasan et al.   CIRCULATION

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Biomarkers for prediction of venous thromboembolism in cancer

(2013) I. Pabinger et al.   BLOOD

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis

(2012) Sonia Seng et al.   JOURNAL OF CLINICAL ONCOLOGY

Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials

(2012) Cihan Ay et al.   THROMBOSIS AND HAEMOSTASIS

Prediction of venous thromboembolism in cancer patients

(2010) C. Ay et al.   BLOOD

Venous thromboembolism and prognosis in cancer

(2010) Alok A. Khorana   THROMBOSIS RESEARCH

Assessing Risk of Venous Thromboembolism in the Patient With Cancer

(2009) Alok A. Khorana et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION